Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ADH1B | P00325 | 1/20 | 0.46 |
| ▸ | ADH1C | P00326 | 1/20 | 0.46 |
| ▸ | ADH1A | P07327 | 1/20 | 0.46 |
| ▸ | ADH4 | P08319 | 1/20 | 0.46 |
| ▸ | ADH7 | P40394 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | GLB1 | P16278 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAN1B1 | Q9UKM7 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3439907 | 1.00 | EPHX1 (0.48) | EPHX1KDM4EADH1BADH1CADH1A | |
| SCHEMBL22899939 | 1.00 | EPHX1 (0.48) | EPHX1KDM4EADH1BADH1CADH1A | |
| SCHEMBL22693050 | 1.00 | EPHX1 (0.48) | EPHX1KDM4EADH1BADH1CADH1A | |
| SCHEMBL23744926 | 1.00 | EPHX1 (0.48) | EPHX1KDM4EADH1BADH1CADH1A | |
| SCHEMBL22790746 | 1.00 | EPHX1 (0.48) | EPHX1KDM4EADH1BADH1CADH1A | |
| SCHEMBL24514269 | 1.00 | EPHX1 (0.48) | EPHX1KDM4EADH1BADH1CADH1A | |
| SCHEMBL22802804 | 1.00 | EPHX1 (0.48) | EPHX1KDM4EADH1BADH1CADH1A | |
| SCHEMBL24379883 | 1.00 | EPHX1 (0.48) | EPHX1KDM4EADH1BADH1CADH1A | |
| SCHEMBL22790745 | 1.00 | EPHX1 (0.48) | EPHX1KDM4EADH1BADH1CADH1A | |
| SCHEMBL5200918 | 1.00 | EPHX1 (0.48) | EPHX1KDM4EADH1BADH1CADH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108047058-A | N, N- dimethyl -4- cyclohexylamino cyclohexyl-methanes and its preparation method and application | 万华化学集团股份有限公司 | 2018-05-18 | — | — | CN | claimed |
| EP-4306111-A2 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2024-01-17 | — | — | EP | disclosed |
| US-20230271974-A1 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF | ABBVIE INC. | 2023-08-31 | — | — | US | disclosed |
| EP-3820574-B1 | 3-(5-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES | NOVARTIS AG (CH) | 2023-08-09 | — | — | EP | disclosed |
| US-20230067476-A1 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2023-03-02 | — | — | US | disclosed |
| WO-2023000114-A1 | ALPHA-FETOPROTEIN BIOCONJUGATES FOR DISEASE TREATMENT | ALPHA CANCER TECHNOLOGIES INC. (CA) | 2023-01-26 | — | — | WO | disclosed |
| US-11185537-B2 | 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2021-11-30 | — | — | US | disclosed |
| CN-105980384-B | Macrocyclic compounds having a heterocyclic P2' group as factor XIA inhibitors | 百时美施贵宝公司 | 2019-11-15 | — | — | CN | disclosed |
| CN-106795161-B | pyrimidinones as factor XIA inhibitors | 百时美施贵宝公司 | 2019-10-15 | — | — | CN | disclosed |
| CN-110305109-A | The indazole of new substituted, preparation method, comprising its pharmaceutical preparation and its be used to prepare the purposes of drug | 拜耳医药股份有限公司 | 2019-10-08 | — | — | CN | disclosed |
| US-20170121276-A1 | HISTONE ACETYLTRANSFERASE MODULATORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-05-04 | — | — | US | disclosed |
| CN-103987697-B | Substituted tetrahydroisoquinoline compounds as factor XIA inhibitors | 百时美施贵宝公司 | 2017-04-26 | — | — | CN | disclosed |
| CN-106470983-A | Big ring picolinamide as antifungal | 美国陶氏益农公司 | 2017-03-01 | — | — | CN | disclosed |
| CN-106459051-A | Macrocyclic FXIA Inhibitors Containing Heterocyclic Groups | 百时美施贵宝公司 | 2017-02-22 | — | — | CN | disclosed |
| EP-2524913-A1 | NITROGENATED HETEROCYCLIC RING DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME | Idemitsu Kosan Co., Ltd. (JP) | 2012-11-21 | — | — | EP | disclosed |
| EP-2352734-A1 | TRICYCLIC NITROGEN COMPOUNDS USED AS ANTIBACTERIALS | Glaxo Group Limited (GB) | 2011-08-10 | — | — | EP | disclosed |
| WO-2010043714-A1 | TRICYCLIC NITROGEN COMPOUNDS USED AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2010-04-22 | — | — | WO | disclosed |
| US-7417053-B2 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED (JP) | 2008-08-26 | — | — | US | disclosed |
| US-20070072898-A1 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED | 2007-03-29 | — | — | US | disclosed |
| US-3959374-A | CONTINUOUS | JEFFERSON CHEMICAL COMPANY, INC. (US) | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072898-A1 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | MAPKAPK2, MAP4K2, MAPKAPK5 | EPHX1 3875/4885KDM4E 1877/4885ADH1B 3807/4885 |
| US-20230271974-A1 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF | TSLP, HRH4, IL4 | EPHX1 1266/4885KDM4E 502/4885ADH1B 524/4885 |
| US-20170121276-A1 | HISTONE ACETYLTRANSFERASE MODULATORS AND USES THEREOF | EP300, KAT2A, HTT | EPHX1 4228/4885KDM4E 721/4885ADH1B 2539/4885 |
| US-20230067476-A1 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | XDH, HTR1D, RXFP1 | EPHX1 840/4885KDM4E 3010/4885ADH1B 1055/4885 |
| US-11185537-B2 | 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | RXFP3, RXFP1, NPY2R | EPHX1 2757/4885KDM4E 2398/4885ADH1B 1356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.